Filing Flows

Filing Flows › 8-K events › Altimmune

Altimmune: creation of a direct financial obligation

Form 8-K filed Oct 29, 2026 · items 2.03

What the filing says

On October 27, 2026, Altimmune, Inc. (the “Company”), has drawn $10.0 million in an aggregate principal amount (“Tranche Three”) from its $125.0 million Loan and Security Agreement, dated as of May 13, 2025 (as amended by the Amendment to Loan and Security Agreement, dated as of November 5, 2025, the “Loan Agreement”),

ScaleThe filing names $125.0M: 1,202× Altimmune's annual revenue ($104K, four times the latest quarter).

Read the filing on SEC EDGAR →

What usually followsAcross 13,268 8-Ks reporting Item 2.03 (new debt or off-balance-sheet obligation) in our universe, the stock's median move the next session was 0.0% (typical size ±1.3%, up 50% of the time); over the following 21 sessions, +1.2%. Every item ranked →

What this kind of filing means

Item 2.03 — Creation of a direct financial obligation. New debt or a guarantee: the amount, the rate and the maturity set the cost of capital and the repayment wall ahead.

Altimmune at a glance

Latest quarterQ4 2025
Revenue$26K
Revenue Y/Y+420%
Operating marginn/m
IndustryPharmaceutical Preparations

Altimmune, Q4 2025: revenue $26K (+420% year over year). The chart follows the revenue to costs, profit and cash.

Altimmune: every quarter, Q/Q and Y/Y, holders and guidance →

Altimmune’s other material 8-Ks

Other recent debt and financing

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.